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The sodium neutral amino acid transporter 3 (SNAT3) is expressed in all three cell types and plays a pivotal role in glutamine transport. Initially cloned from the liver and brain, SNAT3 mediates glutamine transport that is accompanied by the cotransport of 1 Na ϩ and the antiport of 1 H ϩ (8, 14, 19, 23) . As a result, the overall transport mechanism is electroneutral and governed by pH and Na ϩ gradients. This also explains why SNAT3 can be involved in both the uptake and release of glutamine.
Considering the essential roles of glutamine in cellular nutrition and signaling, the hypothesis of this study is that glutamine transport is tightly regulated by nutritional signals and changes in cell growth. The primary sequence of SNAT3 contains a number of putative PKC phosphorylation sites. PKC isoforms are activated by a variety of pathways that are involved in cell growth, migration, and differentiation (34) . PKC is also activated by phospholipid-dependent kinase (PDK-1), which is involved in insulin signaling. The aim of this study was to investigate the possibility of PKC-mediated regulation of SNAT3 and elucidate the mechanism of this potential regulation. Our results show that SNAT3 is rapidly downregulated by activating PKC through the treatment of Xenopus laevis oocytes with PMA. This downregulation occurs in a caveolindependent, dynamin-independent manner and is not a result of the direct phosphorylation of the transporter.
MATERIALS AND METHODS

Plasmids and Constructs
The rat SNAT3 cDNA subcloned into oocyte expression vector pGEM-He-Juel was the same as described previously (8) . An enhanced green fluorescent protein (EGFP)-SNAT3 fusion protein was generated by overlap extension PCR (30) . To this end, the coding region of SNAT3 was amplified using a forward primer, which, in addition to its SNAT3-specific region, contained the final 20 nucleotides of EGFP at its NH2 terminus (5=-GCA TGG ACG AGC TGT ACA AGA TGG AGA TAC CCC GAC AGA C-3=), and a reverse primer (5=-GGA GGT CAT CCT AAT GGT TTC-3=) that was complementary to the 3= end of the SNAT3 cDNA (PCR 1). In a second PCR, EGFP was amplified from plasmid pEGFP-C1 (Clontech, Palo Alto, CA) using a forward primer that has the sequence of the 5= end of the EGFP cDNA coupled to an EcoR I site (5=-CGA ATT CGC CAC CAT GGT GAG CAA G-3=) and a reverse primer that is complementary to the 3= end of the EGFP cDNA but in addition contains the first 20 nucleotides of SNAT3 NH2 terminus (5=-GTC TGT CGG GGT ATC TCC ATC TTG TAC AGC TCG TCC ATG C-3=; PCR 2). Both PCR products were purified with a PCR product purification kit (Qiagen, Castle Hill, Australia). In a third PCR reaction, the 2 PCR products were mixed together with the forward primer of PCR 1 and the reverse primer of PCR 2. The resulting fusion-PCR product was cloned into vector pCR-Blunt II (Invitrogen, Carlsbad, CA). For oocyte expression, the PCR product was excised with EcoR I and cloned into vector pGem-He-Juel. The SNAT1-SNAT3 fusion protein was constructed in an analogous way using the fusion primer (5=-ATT CCA GGA ACA ACC TCT TTT GGG ATG TCG GTG TTC-3= or its complement), which contains parts of both sequences, and the outer primers 5=-CCAGGGGGTACTTAG-GAGGA-3= (specific for rat SNAT3) and 5=-GACATTCGGATT-GATTTCTTGA-3= (specific for rat SNAT1).
The monocarboxylate transporter MCT1 (12) and the amino acid transporter SNAT1 cDNA were used as described previously (2) .
The ␣-and ␤-isoforms of wild-type rat caveolin-1 were amplified from purified rat astrocyte cultures and cloned into the pCR-Blunt II vector (Invitrogen). The sense primers 5=-CCACCATGTCTGG-GGGTAAA-3= and 5=-CCACCATGGCAGACGAGGTG-3= (Kozak sequence in bold, start codon underlined) and antisense primer 5=-TAAGGGGGAGAAAAGCCTTC-3= were used to amplify the ␣-and ␤-isoforms, respectively. Rat caveolin-1 cDNA was then excised using EcoR I and subcloned into the oocyte expression vector pGemHe-Juel. The cloning process was verified by restriction enzyme digestion and sequencing.
The wild-type and K44A mutant rat dynamin-1 cDNA were kindly provided by Dr. Marc G. Caron (Howard Hughes Medical Institute at Duke University). Its sequence is identical to National Center for Biotechnology Information (NCBI) database acc. no. X54531. In a similar manner to rat caveolin-1, the coding sequence was amplified by using the sense primer 5=-ccaccatgggcaaccgcggcatggaa-3= (Kozak sequence in bold, start codon underlined) and antisense primer 5=-tcctcaggggtcactgatagtgattct-3= and cloned into vector pCR-Blunt II (Invitrogen). Subsequently, the rat dynamin-1 cDNA was excised with EcoR I and subcloned into oocyte expression vector pGem-He-Juel.
The human (h) sodium glucose transporter 1 (SGLT1) was kindly provided by Dr. Florian Lang (Institute of Physiology, University of Tübingen), and the human regulatory subunit 1 (RS1) was provided by Dr. Valentin Gorboulev (Institute of Anatomy, University of Würzburg). hSGLT1 and hRS1 were provided as inserts in the pBluescript vector.
For expression, all constructs were linearized with Not I, Sal I, EcoR I, or Xba I and transcribed in vitro with T7 or T3 RNA polymerase in the presence of the cap analog m 7 G(5=)ppp(5=)G at a concentration of 1 mM. Template plasmid was removed by digestion with RNase-free DNase I. Constructs provided in the pBluescript vector were subjected to poly(A) tailing for expression in oocytes. The complementary RNA (cRNA) was purified by phenol/chloroform extraction followed by precipitation with 0.5 volume of 7.5 M ammonium acetate and 2.5 volumes of ethanol. The integrity of the transcript was checked by denaturing agarose gel electrophoresis.
Site-Directed Mutagenesis
Site-directed mutagenesis was performed without subcloning by using the QuikChange II site-directed mutagenesis kit (Stratagene, La Jolla, CA). Briefly, 2 complementary primers were constructed in which the desired mutation was flanked by 15 nucleotides corresponding to the SNAT3 cDNA sequence. The primers were used to amplify the complete cDNA-containing vector by 16 PCR cycles. Subsequently, the template DNA was removed by digestion with DpnI. To verify the mutation after transformation, either restriction enzyme recognition sites were introduced by silent mutagenesis or the product was sequenced. To avoid secondary site mutations that might have been introduced during the amplification reaction, the transport activity of 3 independent clones was determined. The oligonucleotides used for site-directed mutagenesis are listed below. Only the sense sequence is shown in the 5=-to-3= direction. The mutated base is annotated in lowercase letters, and the numbering of the amino acids corresponds to the sequences of rat SNAT3 (14) , rat caveolin-1-␣ (NCBI database acc. no. BC161826), and rat caveolin-1-␤ (NCBI database acc. no. NM_031556). The mutants are designated as wildtype amino acid/position/mutant amino acid:
rSNAT3: T7A: 5=-GAG ATA CCC CGA CAG gCA GAG ATG GTG GAG CTG-3=; T32A: 5=-GCA TGC CCA CGG CAG ACg CCC AGA GGG CT-3=; S52A: 5=-TCC TTC AGC AAA GCg CtA GCA AGG AGC CA-3= T138A: 5=-CGT GCC TTT GGG gCC CCA GGA AAG CTG-3= S314A: 5=-GGA GCT CAA GGA CCC CgC CAA GAG GAA G-3=; T458A: 5=-TCC GAA TCA TGC CTg CaG AGA AGG AGC CT-3=; T466A: 5=-AGC CTG TGA GAT Ctg CCC CCA AAA TCC TG-3=; rCaveolin-1␣: P132L: 5=-ATC TGG GCA GTT GTA CtG TGC ATC AAG AGC TTC-3=; rCaveolin-1␤: P101L: 5=-ATC TGG GCA GTT GTA CtG TGC ATC AAG AGC TTC-3=; S142A: 5=-AGC AAT ATC CGC ATC gcC ACG CAG AAA GAG ATA-3=; T143A: 5=-AAT ATC CGC ATC AGC gCG CAG AAA GAG ATA TGA-3=.
Oocytes and Injections
X. laevis females were purchased from the South African Xenopus facility (Knysna, Republic of South Africa). All animal handling was approved by the Animal Experimental Ethics Committee at the Australian National University (Protocol F.BMB.45.10). The animals were anesthetized for 20 -30 min in ethyl 3-aminobenzoate methanesulfonate salt (MS-222; 1.5 g/l made in tap water; Sigma-Aldrich). Oocytes (stages V and VI) were isolated by collagenase treatment as described previously (11) and allowed to recover overnight. Oocytes were microinjected with 5-10 nl of the desired cRNA in water at a concentration of 1 g/l by using a microinjection device (World Precision Instruments, Berlin, Germany). Noninjected oocytes were used as controls.
Cell Culture
Astroglia-rich primary cultures were prepared from newborn rat brains as previously described (9) but with some modifications. All animal handling was approved by the Animal Experimental Ethics Committee at the Australian National University (Protocol F.BMB.45.10). Briefly, newborn animals were killed by cervical dislocation, and entire brains were passed successively through 2 nylon nets of 211-and 135-m mesh width. The suspended cells of a complete offspring (10 -15 animals) were collected by centrifugation and resuspended in 20 ml of RPMI 1640-5% FCS. After determination of the cell number, cells were diluted in RPMI 1640-5% FCS to a final density of 400,000 cells/ml. Aliquots (5 ml) were dispensed in 60-mm cell culture dishes and incubated in a cell incubator at 37°C 95% air-5% CO 2 for 14 -21 days. Medium was renewed every week. For all experiments, 14-to 28-day-old confluent cultures were used. At least 90% of these cells express glial acidic fibrillary protein. The cultures contain limited numbers of oligodendroglial, ependymal, and microglial cells but are devoid of neurons (data not shown).
HepG2 cells were grown in RPMI 1640-10% FCS in a cell incubator at 37°C 95% air-5% CO 2. Cells were subcultivated at a 1:10 ratio after reaching confluency.
Flux Measurements
Oocytes. For each determination, groups of seven cRNA-injected or noninjected oocytes were washed twice with 4 ml of ND96 buffer (96 mM NaCl, 2 mM KCl, 1.8 mM CaCl 2, 1 mM MgCl2, 5 mM HEPES, titrated with NaOH to pH 7.4). They were then incubated at room temperature in a 5-ml polypropylene tube containing 100 l of the same buffer containing 5 kBq of [U- 14 C]glutamine or [U-14 C]lactate plus unlabeled substrates as required. Single oocytes were placed in scintillation vials and lysed by addition of 200 l of 10% SDS. After lysis, 3 ml of scintillation fluid was added, and the radioactivity was determined by liquid scintillation counting.
Cells. Cells were grown to a density of 4 ϫ 10 6 per 60-mm culture dish in a humidified atmosphere of 5% CO2 in air at 37°C in RPMI supplemented with 5% FCS. All experiments were performed at 37°C. For determining glutamine uptake, growth medium was aspirated, and cells were washed 3 times with 4 ml of modified HBSS (bicarbonatefree, HEPES-containing HBSS: 136.6 mM NaCl, 5.4 mM KCl, 2.7 mM Na2HPO4, 1 mM CaCl2, 0.5 mM MgCl2, 0.44 mM KH2PO4, 0.41 mM MgSO4, 5 mM HEPES, pH 7.8). Subsequently, 4 ml of modified HBSS containing [ 3 H]glutamine and unlabeled glutamine at a final concentration of 100 M and a specific activity of 2,000 dpm/nmol was added to the cells. In addition, the buffer contained alanine and leucine (each 10 mM) to study system N activity selectively (10). After 10 min, transport was stopped by aspirating the transport buffer followed by 3 washing steps with 3 ml of ice-cold modified HBSS. Cells were lysed by addition of 1 ml of 0.1 M HCl. Of the resulting suspension, an aliquot of 900 l was mixed with 3 ml of scintillation cocktail, and radioactivity was determined by liquid scintillation counting. An aliquot part of 100 l was used for protein determination using the Bio-Rad Protein Assay Kit (Bio-Rad Laboratories, Regents Park, NSW, Australia).
Confocal Microscopy
Confocal fluorescence microscopy work was performed using an inverted confocal laser microscope (TCS-SP2-UV; Leica Microsystems, Wetzlar, Germany). Scanning was always taken unidirectionally with a format of 512 ϫ 512 points at a scan speed of 400 Hz. EGFP fluorescence was excited at 488 nm and detected in a window of 500 -600 nm. Oocytes were examined 3-7 days after they had been injected with EGFP-SNAT3 cRNA. Individual oocytes were arranged on a coverslip in a small drop of ND96 and placed on the microscope platform. In this way, the bottom of the oocyte is flattened on the coverslip and is facing the lens. The oocyte membrane was then brought into focus using the eyepiece and light microscopy. The laser power was adjusted so that only a few pixels were above saturation. Subsequently, the setup was switched to confocal scanning mode and visualized on the computer screen. Images were taken in the plane of the largest perimeter every 5 min. This ensured that bleaching of GFP fluorescence was minimized.
Western Blotting and Surface Biotinylation
Twenty-five oocytes were homogenized in 1 ml of homogenization buffer (50 mM Tris·HCl, pH 7.6, 100 mM NaCl, 1 mM EDTA, pH 8.0, 1 mM protease inhibitor) by trituration. The homogenate was spun in a microcentrifuge at 2,000 g for 10 min at 4°C to separate the lipids from the proteins. The supernatant was transferred to a centrifuge tube and spun at 140,000 g for 30 min at 4°C in a Beckman Optima MAX ultracentrifuge (Beckman, Fullerton, CA). The supernatant was discarded, and the pellet was dissolved in 50 l of homogenization buffer containing 4% SDS. The samples were loaded on a 10% polyacrylamide gel and separated at constant voltage (200 V) for 45 min.
To determine plasma membrane expression, 15 oocytes were washed 3 times with 4 ml of ice-cold PBS, pH 8.0. Subsequently, oocytes were incubated in 0.5 ml of sulfo-NHS-LC-Biotin (0.5 mg/ ml; Pierce, Rockford, IL) solution in PBS for 30 min at room temperature. The reagent was removed by washing oocytes 4 times with 4 ml of ice-cold PBS, pH 8.0. Subsequently, oocytes were lysed by incubation in 1 ml of lysis buffer (150 mM NaCl, 20 mM Tris·HCl, pH 7.5, 1% Triton X-100) for 30 -60 min on ice. The lysate was centrifuged at top speed in a tabletop centrifuge for 15 min at 4°C, and the supernatant was mixed with 50 l of streptavidin-coated agarose particles (Pierce). The suspension was incubated at 4°C overnight with slight agitation. Agarose particles were washed 4 times with 1 ml of lysis buffer, and the pellet was subsequently resuspended in 10 l of SDS-PAGE sample buffer. Samples were boiled for 5 min, and an aliquot of 30 l was loaded on the gel.
SNAT3 was detected with a custom-made antibody raised against the peptide sequence N-GEGKGFLQKSPSKEPHFTD-COOH in rabbits (Zymed Laboratories, South San Francisco, CA). A 1:2,000 dilution of the antiserum was used for Western blots. The MCT1 antibody was used as described before (21) . Caveolin was detected with the rabbit polyclonal antibody to caveolin-1 at a 1:2,000 dilution (Abcam, Cambridge, UK). Antibody binding was detected by enhanced chemiluminescence using the ECL system according to manufacturer's instructions using the provided secondary antibody at a dilution of 1:2,000 (Amersham Pharmacia Biotech, Castle Hill, NSW, Australia).
Sucrose Gradient Fractionation
Two hundred oocytes injected with the cRNA of MCT1, SNAT3, and caveolin-␣ were homogenized by trituration in 2 ml of homogenization buffer containing 1 mM EDTA and 20 mM Tris (pH 7.8).
The homogenate was centrifuged twice at 1,000 g at 4°C. A continuous sucrose gradient was created as previously described (37) . Sucrose solutions were made in homogenization buffer. Briefly, 4 ml of 40% sucrose was placed at the bottom of a 12-ml centrifuge tube. This was quickly frozen in liquid nitrogen and layered with 4 ml of 30% sucrose. After freezing, 2 ml of 5% sucrose was layered on the top. The tubes were frozen at Ϫ80°C. The gradients were thawed for 12 h, and 2 ml of oocyte homogenate was pipetted on top of the gradient. After centrifugation for 16 h in an SW41T1 rotor at 100,000 g at 4°C, 1-ml fractions were removed from the top of the sucrose gradient and diluted to 12 ml in homogenization buffer. The membranes were isolated by an additional centrifugation step at 150,000 g at 4°C for 2 h. Pellets were resuspended in homogenization buffer and subjected to Western blotting.
RESULTS
Rapid Downregulation of SNAT3 Activity by PMA
The treatment of oocytes with PMA is known to activate PKC in this cell type (36) . The rat glutamine transporter SNAT3 was expressed in oocytes, and its activity was determined by flux measurements with 100 M [ 14 C]glutamine. Each experiment was repeated at least three times, each with a separate batch of oocytes. Treatment of these oocytes with PMA (100 nM) resulted in a rapid downregulation of SNAT3 activity within 20 min (Fig. 1A) . The downregulation was irreversible (data not shown). Treatment with the PKC inhibitor bisindolylamide or the inactive 4-␣-PMA, by contrast, did not reduce the observed transport activity (Fig. 1, B and C) . This confirms that the observed downregulation was caused by the activation of PKC in the oocytes. The extent of downregulation varied between oocyte batches and the amount of cRNA injected. Lower amounts of injected cRNA favored a greater inhibition of transport activity. This suggests a role of endogenous oocyte components in the regulatory process. However, the transport activity of untreated oocytes was not significantly affected by this manipulation, showing that it was specific for SNAT3. Despite these fluctuations, at least a 50% reduction of SNAT3 activity was observed in all experiments performed in this study. Together, this suggests that the reduction of glutamine transport is caused by a PKC-specific mechanism.
Downregulation of SNAT3 is Specific
The treatment of oocytes with PMA is known to reduce their plasma membrane surface area (29) . To investigate whether the PMA-induced downregulation of SNAT3 activity was transporter-specific, SNAT3 was coexpressed with MCT1 in oocytes. Coexpression of the two transporters did not affect their individual uptake activity. Whereas the treatment of oocytes with PMA (100 nM) for 30 min caused a selective reduction in the rate of glutamine uptake via SNAT3 (Fig. 2A) , lactate uptake mediated by MCT1 remained unaffected (Fig. 2B) . The A: oocytes were injected with 10 ng of rat (r) SNAT3 complementary RNA (cRNA) or remained uninjected in the controls. After an expression period of 2 days, oocytes were incubated in ND96 medium containing PMA (100 nM) for different time periods. Oocytes were also incubated in ND96 medium containing 0.5 or 1 M bisindolylamide (Bis) containing PMA (100 nM; B) or ND96 medium containing 4-␣-PMA (100 nM; C) for 30 min. Subsequently, the uptake of [ 14 C]glutamine (100 M) was determined over an incubation period of 10 min. Each point or bar represents the mean Ϯ SD of uptake activity measured in 7-10 oocytes. One of 3 independent replicates is depicted. ***P Ͻ 0.0001; n.s, no significance. Fig. 2 . Specificity of SNAT3 downregulation by PMA. Oocytes were injected with 10 ng of rSNAT3 cRNA, 5 ng of the monocarboxylate transporter MCT1 cRNA, or a combination of both. After an expression period of 2 days, oocytes were incubated in ND96 medium or in ND96 containing PMA (100 nM). After 30 min, uptake of 100 M [ 14 C]glutamine (A) or uptake of 100 M [ 14 C]lactate (B) was determined over an incubation period of 10 min in ND96 buffer. C: oocytes were injected with 10 ng of SNAT1 cRNA. After an expression period of 2 days, oocytes were incubated in ND96 medium or in ND96 containing 100 nM PMA. Uptake of glutamine was determined as described above. One of 3 repeats is represented. Each bar corresponds to the mean Ϯ SD of uptake measured in 7-10 oocytes. The transport activity of noninjected oocytes has been subtracted. One of 3 experimental repeats is shown. *P Ͻ 0.01, **P Ͻ 0.01. MCT1 activity remained unaffected after PMA treatment. specificity of the regulatory effect of PMA on SNAT3 was further demonstrated by the expression of the related transporter SNAT1. Treatment of oocytes expressing SNAT1 with PMA (100 nM) resulted in only a minimal change in transport activity (Fig. 2C) .
SNAT3 Regulation Does Not Involve Protein Phosphorylation
Based on homology modeling of SNAT3 (13) along the structure of the hydantoin permease Mhp1 (49), the primary sequence of the SNAT3 transporter contains seven putative phosphorylation sites that are accessible from the cytosol. These are residues T7, T32, S52, T138, S314, T458, and T466 (Fig. 3) . Of these sites, T32, S314, T458, and T466 are putative PKC phosphorylation sites that are conserved in mouse, rat, and human sequences. S52 is a nonconserved PKC phosphorylation site. T7 and T138 are two non-PKC phosphorylation sites.
To address the possibility of SNAT3 phosphorylation during downregulation, either directly by PKC or indirectly by another regulatory protein, each of the identified serine and threonine residues was mutated to alanine. The mutants were named T7A, T32A, S52A, T138A, S314A, T458A, and T466A. An additional combined mutant of the five PKC phosphorylation mutations was created to consider the possibility of a synergy between the sites during regulation. The transport activity of the mutants was similar to that of the wild-type transporter, demonstrating the expression of the mutated proteins at the cell surface. On treatment with PMA (100 nM) for 30 min, the inhibition of transport activity was not only 
Remaining activity, % Each value represents the mean Ϯ SD of the percentage of remaining activity across n independent experiments of 7-10 oocytes each. Oocytes were injected with 5-10 ng of wild-type or mutated sodium neutral amino acid transporter 3 (SNAT3) or with SNAT3-SNAT1 complementary RNA (cRNA). After an expression period of 3 days, uptake of [ 14 C]glutamine (100 M) for 20 min was determined in oocytes that had been treated for 30 min with PMA (100 nM) and compared with glutamine uptake in control oocytes. The effect of PMA on wild-type SNAT3 was compared with its effect on SNAT3 mutants missing 7 phosphorylation sites individually or a mutant missing all 5 putative PKC phosphorylation sites (PKC1-5). In a separate experiment, the effect of PMA on a SNAT1-SNAT3 fusion protein was determined. The uptake activity of noninjected oocytes was subtracted in all experiments. For every mutant, P Ͻ 0.0001 when comparing control (ND96 medium-treated) and PMA-treated oocytes. The phosphorylation mutants did not abolish SNAT3 downregulation by PMA. Fig. 3 . Location of putative phosphorylation sites in the primary structure of SNAT3. Depicted is the predicted secondary structure of rat SNAT3 as suggested by homology modeling along the structure of the hydantoin permease Mhp1 (49). The structural plot was computed using the transmembrane protein display software (http://www.sacs.ucsf.edu/TOPO/topo.html). Transmembrane helices have been numbered, and putative phosphorylation sites used for mutagenesis studies have been highlighted. The translocation pore is depicted in the center. observed in oocytes expressing the wild-type transporter, but also in oocytes expressing the phosphorylation mutants (Table 1) . These results suggest that the regulatory effect of PMA on SNAT3 activity is not due to direct transporter phosphorylation but involves additional endogenous oocyte proteins.
The NH 2 terminus of SNAT3 is the largest cytosolic domain. The COOH terminus is extracellular, and the intracellular loops are relatively small regions (Fig. 3) . In an attempt to identify the regulatory regions of SNAT3 that could potentially interact with oocyte endogenous proteins, the SNAT3 cytosolic NH 2 terminus was replaced with the NH 2 terminus of the related SNAT1 protein. Although the fusion protein displayed only 40% of the wild-type transport activity after 5 days (data not shown), it was still downregulated after PMA treatment (Table 1) .
SNAT3 Downregulation Involves Protein Trafficking
A reduction in transport activity can occur due to the modification of the transporter or its retrieval from the plasma membrane into vesicular compartments. The results described above indicate that the PMA-induced downregulation of SNAT3 activity does not involve transporter phosphorylation. To investigate the possibility of SNAT3 retrieval from the oocyte plasma membrane on PMA treatment, an EGFP-SNAT3 fusion protein was constructed, and its expression was monitored by confocal microscopy. We (15) have previously shown that the laser beam of the confocal microscope only penetrates the outermost layer of the oocyte. Membrane proteins that are retrieved from the plasma membrane thus become invisible. Using this feature, the surface expression of EGFP-SNAT3 was observed in oocytes. Treatment of EGFP-SNAT3-expressing oocytes with PMA (100 nM) resulted in a decrease in observed fluorescence (Fig. 4A) . The time course of decreasing fluorescence followed a similar pattern as the reduction in transport activity (Fig. 1A ) and corresponded to a concomitant decrease in glutamine uptake (Fig. 4B) .
As judged by the total amount of protein detected in Western blots, the decrease in the amount of observed fluorescence was not due to protein degradation (Fig. 5A) . Evidence of the surface retrieval of SNAT3 was also obtained from surface biotinylation experiments that demonstrated a marked reduction in the detected immunoreactive material after PMA treatment. No significant reduction was seen on treatment with the inactive 4-␣-PMA (Fig. 5B) . Furthermore, biotinylation of SNAT3 before PMA treatment did not alter the detectable signal of the transporter after homogenization and streptavidin pull-down (Fig. 5C ).
SNAT3 Retrieval is Dynamin Independent
The internalization of many membrane proteins occurs through clathrin-or caveolin-coated pits (16) . In either case, the detachment of the pits from the plasma membrane is mediated by the GTPase dynamin. To investigate the mechanism of SNAT3 retrieval from the plasma membrane, the wild-type or dominant-negative mutant (K44A) of dynamin was expressed in conjunction with SNAT3 in oocytes. Coexpression of the K44A mutant had no effect on the previously observed inhibition of SNAT3 transport activity (Fig. 6A) . The functionality of the obtained dynamin K44A mutant was tested by examining its inhibitory effect on the downregulation of SGLT1 by RS1, which has been reported to involve dynamin (48) . Since the K44A mutant was able to abolish the regulatory effect of RS1 on SGLT1 (data not shown), the lack of an effect on the regulation of SNAT3 was considered evidence against an involvement of dynamin. This notion was further examined by treating SNAT3 oocytes with the dynamin inhibitor Dynasore (30 M) for 10 min before PMA (100 nM) treatment. Inhibition of dynamin function by this compound did not affect the PMA-induced downregulation of SNAT3 activity (Fig.  6B) , confirming that the regulation occurs in a dynaminindependent manner.
SNAT3 Trafficking is Influenced by Caveolin
To further understand the mechanism of SNAT3 downregulation, the role of caveolin in transporter retrieval was examined. Oocytes were coinjected with the cRNA of SNAT3 and either wild-type rat caveolin-␤ or its dominantnegative (P101L) mutant. Surprisingly, the coexpression of the P101L mutant with SNAT3 completely abolished SNAT3 activity before any experimental treatment compared with those coinjected with SNAT3 and wild-type caveolin or SNAT3 alone (Fig. 7A) . Surface biotinylation experiments revealed that this downregulation was accompanied by a reduced amount of immunoreactive material detected in oocytes coinjected with SNAT3 and the P101L mutant (Fig. 7B) . The specificity of this downregulation was tested by coexpressing wild-type and dominant-negative caveolin-␤ mutants with MCT1. The P101L mutant displayed no effect on MCT1 transport activity in the presence or absence of PMA (data not shown). Although this revealed a novel trafficking mechanism for SNAT3, it did not explain the role of caveolin in transporter retrieval.
To circumvent the effect of the P101L mutant on SNAT3 expression, the wild-type and dominant-negative caveolin-␤ cRNA were injected 2 days after injection of SNAT3. Surface biotinylation experiments demonstrated that this manipulation brought SNAT3 expression in these oocytes to a similar level to those expressing SNAT3 alone (Fig. 7B) . This effect was also seen in the transport activity (Fig. 8A) . In addition, the previously observed PMA-induced downregulation of SNAT3 activity was abolished in the oocytes expressing SNAT3 and the dominant-negative P101L mutant. This strongly suggests that caveolin influences both the insertion into and retrieval of SNAT3 from the oocyte plasma membrane.
Caveolin proteins exist in 2 isoforms. Although the ␣-isoform contains 31 additional amino acids at the NH 2 terminus Proteins were detected with a SNAT3-specific antibody. The SNAT3-specific band is indicated by an arrow. "ϩ" Indicates treatment with 100 nM PMA or 4-␣-PMA (as indicated), whereas "Ϫ" represents treatment with ND96 to noninjected (n.i) or SNAT3-expressing oocytes.
of the protein, no functional differences between the 2 isoforms have yet been reported (43) . In accordance, dominant-negative (P132L) caveolin-␣ also abolished the PMAinduced downregulation of SNAT3 activity in oocytes (Fig.  8B) . Furthermore, sucrose gradient fractionation of oocytes expressing SNAT3, MCT1, and caveolin-␣ revealed that caveolin and SNAT3 colocalize in the membrane domains of the oocyte (Fig. 9) . MCT1, however, was primarily detected in 3 of the 6 fractions that contained caveolin-␣.
Since the downregulation of SNAT3 was not due to direct transporter phosphorylation, the possibility of caveolin phosphorylation in the regulatory process was considered. Two putative PKC phosphorylation sites were identified on the rat caveolin-␤ sequence. The serine and threonine residues were mutated to alanine, and the mutants were called S142A and T143A. However, the coexpression of these mutants with SNAT3 did not alter the PMA-induced downregulation of transport activity (data not shown).
Regulation of System N in Cell Culture
System N activity mediated by SNAT3 can be selectively observed by addition of 10 mM each alanine and leucine to the transport buffer (10) . These two amino acids block glutamine transport via glutamine-accepting amino acid transporters SNAT1/5, LAT2, ASCT2, y ϩ LAT1/2, B 0,ϩ , and B 0 (27) . As a result, glutamine transport activity reflects system N activity in the presence of these two amino acids. Addition of PMA to cultured astrocytes and HepG2 cells reduced system N-like glutamine uptake activity in the latter cell type but not in the former (Fig. 10) . Both cell types express SNAT3 as reported previously (4, 27) .
DISCUSSION
In this study, we report that the transport activity of the glutamine transporter SNAT3 is rapidly reduced on PKC activation by phorbol esters via a specific trafficking mechanism in oocytes. In light of the pivotal role of SNAT3 in Fig. 7 . PMA-independent downregulation of SNAT3 by dominant-negative caveolin-␤ (P101L). Oocytes were injected with 5 ng of SNAT3 and 5 ng of caveolin-␤ cRNA (wild-type or P101L mutant as indicated). A: after 3 days of expression, oocytes were incubated for 30 min in ND96 (0 nM PMA) or ND96 containing PMA (100 nM). Uptake of 100 M [ 14 C]glutamine was measured for 25 min. Each bar corresponds to the mean Ϯ SD of uptake measured in 7-10 oocytes. The transport activity of noninjected oocytes has been subtracted. ***P Ͻ 0.0001. One of 3 experimental repeats is shown. B: oocytes were also injected with 5 ng of caveolin cRNA (wild-type or P101L mutant) after 2 days of SNAT3 expression (indicated as day 2). After 2 more days of expression, these untreated oocytes were subjected to surface biotinylation to assess the amount of protein on the plasma membrane. The SNAT3-specific band is indicated by the arrow. Cav, caveolin.
glutamine metabolism, it is not surprising that the transporter is tightly regulated by multiple mechanisms. SNAT3 has previously been reported as a target of the ubiquitin ligase Nedd-4-2 in oocytes, an action that is reversed by the coexpression of the protein kinase SGK1 (6) . More recent findings reveal that glucocorticoids upregulate SNAT3 expression in the kidney in response to metabolic acidosis (33) . The regulation of transport activity by internalization has been reported for several transporters such as the dopamine and norepinephrine transporters of the SLC6 family (7, 32) . Downregulation of transport activity in response to phorbol esters has also been reported in oocytes (22, 29, 40) . Transporter retrieval was accompanied by a reduction in the total plasma membrane surface area for the regulation of the glucose transporter SGLT1 and peptide transporter PEPT1. Although the reduction of plasma membrane surface area in SNAT3-expressing oocytes is still a possibility, our results indicate that the PMA-induced trafficking of SNAT3 is a highly specific process, as evidenced by the lack of an effect on MCT1. The specificity of the mechanism reveals the presence of particular regions or motifs on SNAT3 that are recognized for retrieval. However, experiments with the SNAT1-SNAT3 fusion protein showed that this targeting region is not part of the SNAT3 NH 2 terminus.
The primary sequence of SNAT3 revealed seven putative phosphorylation sites located intracellularly. Several transporters regulated by PKC are known to be phosphorylated during the process (20, 32) . However, our data obtained from mutagenesis studies refute the prospect of SNAT3 phosphoryla- Fig. 8 . Suppression of PMA action by dominant-negative caveolin. Oocytes were injected with 5 ng of SNAT3 cRNA. After 2 days of expression, the same oocytes were injected with 5 ng of caveolin-␤ cRNA (wild-type or P101L mutant as indicated; A) or 2 ng of caveolin-␣ cRNA (wild-type or P132L mutant as indicated; B). After 2 more days of expression, oocytes were incubated for 30 min in ND96 (0 nM PMA) or ND96 containing PMA (100 nM). Uptake of 100 M [ 14 C]glutamine was measured for 25 min. Each bar corresponds to the mean Ϯ SD of uptake measured in 7-10 oocytes. The transport activity of noninjected oocytes has been subtracted. One of 4 experimental repeats is shown. ***P Ͻ 0.0001. Fig. 9 . Colocalization of SNAT3 and caveolin. Two hundred oocytes were injected with 5 ng of SNAT3 and 10 ng of MCT1 cRNA. After 2 days of expression, the same oocytes were injected with 2 ng of caveolin-␣ cRNA. After 2 more days of expression, oocytes were homogenized and analyzed on a continuous sucrose gradient and detected with caveolin-(A), SNAT3-(B), and MCT1-specific (C) antibodies. The presence of each protein is indicated by the arrow. tion in the PMA-induced downregulation of transport activity. Although the extent of downregulation always exceeded 50%, there was still some variability between oocyte batches. This only strengthens the possibility of an involvement of oocyte endogenous proteins as opposed to direct transporter phosphorylation in the regulatory process.
Moreover, our results suggest that SNAT3 is internalized into submembranous compartments. Protein degradation by endogenous ubiquitination processes was excluded as the total amount of protein detected in Western blots remained constant even after PMA treatment. Dynamin is a GTPase that is responsible for the detachment of clathrin-or caveolin-coated pits in the process of internalization of several membrane proteins (16) . Our results indicate that SNAT3 is internalized in a dynamin-independent, caveolin-dependent manner. However, caveolin-dependent endocytosis also requires dynamin for the detachment of coated pits (35) . Since SNAT3 and caveolin colocalize in the lipid raft domains, it is possible that the transporter is specifically retrieved into caveolin-coated pits that remain inaccessible just below the plasma membrane surface and are not dynamic. Type 2 caveolae, which can move just beneath the plasma membrane, exhibit such behavior and are known to be highly immobile structures that are regulated by PKC␣ (44, 45) . Caveolae are also associated with myristoylated alanine-rich C kinase substrate (MARCKS) proteins that are major targets of PKC␣ and are involved in the reorganization of the actin cytoskeleton, which appears to be essential for caveolae formation (46) . A plausible mechanism for SNAT3 regulation would thus involve the activation of PKC␣, phosphorylation of MARCKS, reorganization of the actin cytoskeleton, followed by the withdrawal of SNAT3 into caveolae.
Our results also indicate a forward trafficking mechanism for SNAT3 from endosomes to the plasma membrane that involves caveolin. Although the external stimulus to enhance this trafficking has not yet been identified, SNAT3 expression is known to be upregulated by glucocorticoids under conditions of metabolic acidosis in the kidney (33) and in response to changes of amino acid composition in hepatocytes and astrocytes (5, 10) .
The results of this study indicate that SNAT3 is a strictly regulated glutamine transporter that is sensitive to activation of PKC by PMA. Experiments in cultured cells suggest that system N is differentially regulated at a cellular level. Although system N activity was not reduced by PMA incubation of cultured astrocytes, a significant decrease of transport activity was observed in HepG2 cells. System N activity in these cell types can be attributed to either SNAT3 or SNAT5 (19, 41) . Although it is difficult to determine the individual contribution of these two transporters to glutamine transport, the downregulation of system N in HepG2 cells is consistent with the downregulation observed in oocytes.
SNAT3 is found both in perivenous and periportal hepatocytes in the liver (14, 23) . In periportal hepatocytes, SNAT3 is mainly involved in the removal of glutamine from the incoming portal blood to provide ammonia for urea synthesis (24, 38) . In perivenous hepatocytes, the prevalent function of SNAT3 is to release glutamine, which is synthesized during the detoxification of ammonia. HepG2 cells express both glutamine synthetase and SNAT3 (4) and release glutamine when challenged with elevated levels of ammonia. However, HepG2 cells, like many other fast-growing cell lines, use glutamine as a building block and an energy metabolite. In line with this notion, glutamine deprivation abolishes growth of HepG2 cells (4) . To use glutamine effectively, hepatoma cells not only express SNAT3, but also upregulate glutamine transporters ASCT2 and SNAT2 (4) . In contrast to many other cell types where PMA has a mitogenic effect by activating the MAPK pathway, incubation of HepG2 cells with PMA causes a reduction of growth (18) . This may be a direct consequence of the shutdown of glutamine transporters, such as SNAT3 and ASCT2. ASCT2 activity is also rapidly downregulated in colon carcinoma cells (42) after treatment with phorbol esters. Glutamine uptake and release via specific transporters is thus vital for cell growth and is tightly regulated at multiple levels. In this study, we report for the first time that glutamine uptake via SNAT3 is regulated at two levels, downregulation that is accompanied by transporter retrieval from the oocyte plasma membrane and a forward-trafficking mechanism, both of which are controlled by caveolin. Whereas the activation of PKC via PMA governs SNAT3 retrieval in oocytes, the external stimuli governing the forward trafficking of the transporter are yet to be elucidated.
